TIDMFDBK

RNS Number : 7086D

Feedback PLC

30 June 2021

Feedback plc

Board Update

London, 30 June 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that Simon Sturge has resigned as a Non-Executive Director of the Company to focus on his other commitments.

Rory Shaw, Chairman of Feedback, commented:

"We would like to thank Simon for his significant and valuable contributions over the past three years. Simon has brought tremendous experience, guidance and insight to the Board and he leaves with Feedback in a stronger position than ever. We wish him well for the future."

Simon Sturge, added:

"I have really enjoyed my time on the Board of Feedback and I believe that the Company is entering into a really exciting phase in its continued development."

Enquiries:

 
 Feedback plc                          +44 (0)1954 718072 
  Tom Oakley, CEO                       IR@fbk.com 
 
  Feedback media: 
  Nick Mayhew, Chief Marketing Lead     +44 (0) 7736 065353 
 
 Allenby Capital Limited (Nominated 
  Adviser) 
  David Worlidge / Vivek Bhardwaj      +44 (0)20 3328 5656 
 
 Peterhouse Capital Limited (Joint 
  Broker) 
  Lucy Williams / Duncan Vasey         +44 (0)20 7469 0936 
 
 Stanford Capital Partners Limited 
  (Joint Broker) 
  Patrick Claridge / John Howes        +44 20 3815 8880 
 
 Walbrook PR Ltd                       Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Paul McManus/Nick Rome/Nicholas       07980 541 893 or 07748 325 236 or 
  Johnson                               07884 664 686

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFLFFSRTIIVIL

(END) Dow Jones Newswires

June 30, 2021 10:30 ET (14:30 GMT)

Feedback (LSE:FDBK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Feedback Charts.
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Feedback Charts.